PATENT CLAIM ANALYSIS

Application Number: 15918955
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "229500"]

Abstract:
The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.

Claim (Index 37):
The long-acting injectable composition of  claim 36 , wherein the one or more other therapeutic agents are selected from anti-depressive agents such as compounds that modulate GABA activity, a GABA-B agonist, a 5-HT modulator, a melatonin agonist, an ion channel modulator, a serotonin-2 antagonist/reuptake inhibitor (SARIs), an orexin receptor antagonist, an H3 agonist, a noradrenergic antagonist, a galanin agonist, a CRH antagonist, human growth hormone, a growth hormone agonist, estrogen, an estrogen agonist, a neurokinin-1 drug; and antipsychotic agents, in free or pharmaceutically acceptable salt form.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 90.0
- Lexical Diversity: 2.0
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15101874', '15301895', '15467867', '12994560', '14066987']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7643315272066913
- 35 USC 102 Novelty (BERT): 0.5346686603768404
- Combined Prediction Score: 0.7413652405237062
- Mean Citation Score: 244.05284
- Max Citation Score: 368.6936
- Similarity Product: 346.1664187896728

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test